[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100159816":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":12,"responsibleParty":34,"collaborators":10,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":10,"eligibilityCriteria":42,"healthyVolunteers":39,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":10,"studyType":49,"phases":10,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":60,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":10,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Federal University of São Paulo","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Tacrolimus, Everolimus",null,"Immunosuppression is the same for all patients in the study until the period between the 3rd and 5th weeks, when patients will be randomized to initial regimen and remain or be converted to everolimus tacrolimus.",[13],{"facility":14,"status":15,"city":16,"state":16,"zip":10,"country":17,"countryCode":18,"cosmosGeoPoint":19,"geoPoint":24,"contacts":25},"Hospital Israelita Albert Einstein","RECRUITING","São Paulo","Brazil","BR",{"type":20,"coordinates":21},"Point",[22,23],-46.63611,-23.5475,{"lat":23,"lon":22},[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Lucio Requião Moura","CONTACT","55-11","lrequiao@nefro.epm.br",{"name":32,"role":33,"phone":10,"phoneExt":10,"email":10},"Alvaro Pacheco-Silva, Doctor","PRINCIPAL_INVESTIGATOR",{"type":10,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":35,"oldOrganization":36},"Alvaro Pacheco e Silva Filho","Federal University of Sao Paolo","100159816","comparison-of-two-immunosuppressive-regimens-in-kidney-transplant-recipients-with-deceased-donors-with-the-aim-of-preventing-the-development-of-fibrosis--atrophy-of-reducing-the-incidence-of-cytomegalovirus-infection-100159816",false,"NCT01353053","Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis \u002F Atrophy of Reducing the Incidence of Cytomegalovirus Infection","Inclusion Criteria:\n\n* Patients with BMI below 30,\n* first transplants with PRA \\\u003C 30,\n* no contraindication for induction Thymoglobuline,\n* age 18 years or younger than 70 years.\n\nExclusion Criteria:\n\n* patients with a BMI above 30\n* retransplantation\n* patients hypersensitized with PRA \\> 30\n* compared with Thymoglobulina indication for induction\n* age under 18 or over 70 years","ALL","18 Years","70 Years",{"count":47,"type":48},82,"ESTIMATED","OBSERVATIONAL","The aim of this the study is to the assess whether the graft and patient survival, rejection rates and renal graft function after the first year will not differ between both study arms. The investigators will also the evaluate the reduction in the incidence of cytomegalovirus the and improvement of renal function of the everolimus after 1 year.",[52,53],"Disorder of Transplanted Kidney","Cytomegalovirus Infections",[55,56,57,58,59],"Immunosuppression","Cytomegalovirus","Renal Transplant","Atrophy\u002Finterstitial","Conversion of tacrolimus everolimus","UNKNOWN","2011-05-11",{"date":63,"type":48},"2011-05-12",{"date":65,"type":10},"2010-07",{"name":5,"class":6},1]